APHL develops, promotes, updates, and disseminates guidance related to Tuberculosis (TB) testing best practices nationwide in close collaboration with the Division of Tuberculosis Elimination (DTBE) at CDC. Commonly considered a disease of the past, TB is resurging in new and virtually untreatable forms that have the potential to cause debilitating disease in our nation's most vulnerable residents. Diagnostic laboratories play instrumental roles in fighting TB by identifying and isolating
Mycobacterium tuberculosis, the causative agent of TB disease through the use and application of novel diagnostic techniques.
Education and Training
A set of free and interactive training modules, the “Essentials for the Mycobacteriology Laboratory: Promoting Quality Practices” are an on-demand resource to promote competency, quality and safety in common mycobacteriology testing practices. Designed for laboratorians at all levels of experience, each module in the series is complimented by references and resources. Modules are also available in PDF format (with and without narrative notes) for use in laboratory training programs.
Drug Susceptibility Testing
In 2015, APHL in collaboration with CDC established a
National PHL Drug Susceptibility (DST) Reference Center for
Mycobacterium tuberculosis to provide quality-assured drug susceptibility testing for eligible US public health laboratories. The reference center serves as an extension of CDC’s Division of TB Elimination Laboratory Branch providing services that are harmonized with and complementary to those available at CDC.
The TB subcommittee has developed and published white papers on issues in
Mycobacterium tuberculosis Complex (MTBC) drug susceptibility testing, covering current guidelines, recommendations and research findings.
In 2019, APHL and CDC updated the Mycobacterium Tuberculosis: Assessing Your Laboratory, a tool designed originally in 1995, to assist laboratories in the assessment of the quality of their laboratory’s TB diagnostic practices. The most recent updates were made to reflect changes to TB diagnostics over the last six years since the 2013 version was published. The 2019 version was updated throughout to align with current guidelines and recommendations and additional questions were added to address safety considerations and inactivation for downstream applications as well as more clear items around employee competency. Learn more.